Navigation Links
Bioniche Converts a Portion of its Debt to Equity
Date:3/27/2008

- results in US$1.75 million of new available funds -

BELLEVILLE, ON, March 27 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that the Company has exercised its right under the agreement to repay US$1.75 million of its secured revolving credit facility with Valens U.S. (formerly Laurus Master Funds) in common shares.

The conversion is in accordance with the formula set out in the original agreement signed in 2005. The shares will be priced at the ten day market average less 15% which equates to 2,671,900 shares. In addition, the Company will issue 200,000 five-year warrants at market price ($0.77 per share) in exchange for Valens waiving certain volume restrictions relating to the conversion under the agreement. There is no penalty attached to this repayment.

This conversion will result in new available funds of US$1.75 million. As a result, the Company's capacity to borrow under the revolving credit facility after the conversion will be approximately US$3.2M, determined by a formula which measures existing levels of inventory and accounts receivable.

"Again we appreciate the support and flexibility of our bankers, Valens U.S.," said Patrick Montpetit, Chief Financial Officer of Bioniche Life Sciences Inc. "This private placement will improve our liquidity as we continue to execute our Phase III clinical development program with Urocidin in bladder cancer and begin the construction of a facility in which to scale-up production of our E. coli O157:H7 cattle vaccine in Belleville, Ontario."

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of Canada's Top Ten Life Sciences Companies for 2008. For more information, please visit http://www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.


'/>"/>
SOURCE Bioniche Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Receives Fast Track Designation For First-Line Bladder Cancer Therapy
2. Bioniche Pharma Chooses TrackWise for its Deviation Control Solution
3. Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM)
4. Bioniche Reports Fiscal 2008 Second Quarter
5. USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
6. Bioniche Amends Terms of Convertible Debt with Laurus Master Funds
7. Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario
8. Bioniche Reports Fiscal 2008 First Quarter
9. Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference
10. Media Advisory - Bioniche Discusses USDA Comment on E. coli O157:H7 Cattle Vaccine Field Trial
11. Bioniche Receives Comment from USDA on a Field Trial for E. coli O157:H7 Cattle Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology: